Preparing your results

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.

A paucity of validated kinase targets in human multiple myeloma has delayed clinical deployment of kinase inhibitors in treatment strategies. We therefore conducted a kinome-wide small interfering RNA (siRNA) lethality study in myeloma tumor lines bearing common t(4;14), t(14;16), and t(11;14) translocations to identify critically vulnerable kinases in myeloma tumor cells without regard to preconceived mechanistic notions. Fifteen kinases were repeatedly vulnerable in myeloma cells, including AKT1, AK3L1, AURKA, AURKB, CDC2L1, CDK5R2, FES, FLT4, GAK, GRK6, HK1, PKN1, PLK1, SMG1, and TNK2. Whereas several kinases (PLK1, HK1) were equally vulnerable in epithelial cells, others and particularly G protein-coupled receptor kinase, GRK6, appeared selectively vulnerable in myeloma. GRK6 inhibition was lethal to 6 of 7 myeloma tumor lines but was tolerated in 7 of 7 human cell lines. GRK6 exhibits lymphoid-restricted expression, and from coimmunoprecipitation studies we demonstrate that expression in myeloma cells is regulated via direct association with the heat shock protein 90 (HSP90) chaperone. GRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.

Pubmed ID: 19996089


  • Tiedemann RE
  • Zhu YX
  • Schmidt J
  • Yin H
  • Shi CX
  • Que Q
  • Basu G
  • Azorsa D
  • Perkins LM
  • Braggio E
  • Fonseca R
  • Bergsagel PL
  • Mousses S
  • Stewart AK



Publication Data

February 25, 2010

Associated Grants

  • Agency: NCI NIH HHS, Id: P50 CA100707
  • Agency: NCI NIH HHS, Id: P50 CA100707-070008
  • Agency: NCI NIH HHS, Id: R01 CA133966
  • Agency: NCI NIH HHS, Id: R01 CA133966-02
  • Agency: NCI NIH HHS, Id: R01 CA136671
  • Agency: NCI NIH HHS, Id: R01 CA136671-02
  • Agency: NCI NIH HHS, Id: R01CA129009-03

Mesh Terms

  • Animals
  • Cell Line, Tumor
  • Chromosomes, Human
  • G-Protein-Coupled Receptor Kinases
  • Gene Silencing
  • HSP90 Heat-Shock Proteins
  • Humans
  • Mice
  • Multiple Myeloma
  • Phosphorylation
  • Protein Kinase Inhibitors
  • Protein Kinases
  • RNA, Small Interfering
  • STAT3 Transcription Factor
  • Translocation, Genetic